"The key to success is to bring value – that is Lupin’s strategy in Canada and it has worked very well."
In Conversation
"CFI has existed for 20 years and in that time, we have invested, with the federal and provincial governments and others, CAD 17 billion dollars in…
"At Sanofi Genzyme, we do not see our activities as mere transactions, but an investment in working with the healthcare systems and patients within Canada."
"Intracrinology is a newly established field within women’s health. There is definitely a huge and pressing unmet medical need here. To give an indication, in the…
"In the past three years, my team and I have developed and implemented a lot of processes, structure and governance in order to maximize the impact…
"We are present throughout the entire continuum of care from prevention to treatment across different therapeutic areas, as well as a wide range of functions, from…
"Canada offers relatively transparent institutions, a demand for innovation, and leading clinical practice and expertise."
"Market access timelines are extending, not just in terms of obtaining market approval but also all of the hurdles that occur post-approval."
Interview: Douglas Clark – Executive Director, Patented Medicines Price Review Board (PMPRB), Canada
"While our powers have changed a bit since 1987, our mandate is the same: to protect Canadian consumers from excessively-priced patented medicines, as well as to…
"The entire pharmaceutical supply chain has had to adapt over the past five years and it will be the case for the next few years –…
"People often ask me, why did I not retire? I did not even take the day off!"
"Healthcare stands at 50 percent of the provincial budget this year. It shows how critical it is to support decision makers with reliable knowledge."
